Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by Redbaron2211on Nov 24, 2020 7:49pm
111 Views
Post# 31966640

RE:RE:RE:RE:RE:RE:RE:RE:RE:Sernova Mgmt (or lack thereof)

RE:RE:RE:RE:RE:RE:RE:RE:RE:Sernova Mgmt (or lack thereof)Sonny I just have a hard time believing we can find some one that would actually make a difference or preform better then Philip especially on a small budget.  Kind of feels like putting the cart before the horse here as I believe Philip will pull through.  Apart from impatient investors there is only evidence to support the thesis that something big is brewing.  I'm happy to wait at least until the end of the 3 month extension to see what he can pull off before I will consider selling or calling for a new CEO.  My 2 cents anyways.
Bullboard Posts